Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

The projected prevalence of comorbidities and multimorbidity in people with HIV in the United States through the year 2030

View ORCID ProfileKeri N Althoff, Cameron Stewart, Elizabeth Humes, Lucas Gerace, Cynthia Boyd, Kelly Gebo, Amy C Justice, Emily Hyle, Sally Coburn, Raynell Lang, Michael J Silverberg, Michael Horberg, Viviane D Lima, M John Gill, Maile Karris, Peter F Rebeiro, Jennifer Thorne, Ashleigh J Rich, Heidi Crane, Mari Kitahata, Anna Rubtsova, Cherise Wong, Sean Leng, View ORCID ProfileVincent C Marconi, Gypsyamber D’Souza, Hyang Nina Kim, Sonia Napravnik, Kathleen McGinnis, Gregory D Kirk, Timothy R Sterling, Richard D Moore, Parastu Kasaie
doi: https://doi.org/10.1101/2022.11.04.22281891
Keri N Althoff
1Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Keri N Althoff
  • For correspondence: kalthoff@jhu.edu
Cameron Stewart
1Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Elizabeth Humes
1Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lucas Gerace
1Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Cynthia Boyd
1Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA
2Division of Geriatric Medicine and Gerontology, Department of Medicine, Johns Hopkins School of Medicine, Baltimore, MD, USA
3Department of Health Policy and Management, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kelly Gebo
4Division of Infectious Diseases, Department of Medicine, Johns Hopkins School of Medicine, Baltimore, MD, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Amy C Justice
5Yale Schools of Medicine and Public Health, New Haven, Connecticut, USA
6Veterans Affairs Connecticut Healthcare System, West Haven, CT, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Emily Hyle
7Harvard Medical School and the Division of Infectious Diseases, Massachusetts General Hospital, Boston, MA, USA
8Harvard University Center for AIDS Research, Boston, MA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sally Coburn
1Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Raynell Lang
9Department of Medicine, University of Calgary, Calgary, Alberta, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michael J Silverberg
10Division of Research, Kaiser Permanente Northern California, Oakland, CA, USA and Department of Health Systems Science, Kaiser Permanente Bernard J. Tyson School of Medicine, Pasadena, CA, USA
11Department of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, CA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michael Horberg
12Mid-Atlantic Permanente Research Institute, Kaiser Permanente Mid-Atlantic Permanente Medical Group, Rockville, MD USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Viviane D Lima
13Epidemiology and Population Health Program, British Columbia Centre for Excellence in HIV/AIDS, Vancouver, British Columbia, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
M John Gill
9Department of Medicine, University of Calgary, Calgary, Alberta, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Maile Karris
14Department of Medicine, University of California San Diego, San Diego, CA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Peter F Rebeiro
15Departments of Medicine and Biostatistics, Vanderbilt University School of Medicine, Nashville, TN, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jennifer Thorne
16Department of Ophthalmology, Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, MD, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ashleigh J Rich
17Department of Social Medicine, University of North Carolina, Chapel Hill, NC, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Heidi Crane
18Division of Allergy and Infectious Diseases, Departments of Medicine and Epidemiology, University of Washington, Seattle, Washington, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mari Kitahata
18Division of Allergy and Infectious Diseases, Departments of Medicine and Epidemiology, University of Washington, Seattle, Washington, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Anna Rubtsova
19Department of Behavioral, Social, and Health Education Sciences, Emory University Rollins School of Public Health, Atlanta, GA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Cherise Wong
20Division of Worldwide Research and Development, Pfizer Inc., New York, NY, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sean Leng
2Division of Geriatric Medicine and Gerontology, Department of Medicine, Johns Hopkins School of Medicine, Baltimore, MD, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Vincent C Marconi
21Division of Infectious Disease, Emory School of Medicine, Atlanta, GA, USA
22Atlanta Veterans Affairs Health Care System, Decatur, GA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Vincent C Marconi
Gypsyamber D’Souza
1Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hyang Nina Kim
18Division of Allergy and Infectious Diseases, Departments of Medicine and Epidemiology, University of Washington, Seattle, Washington, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sonia Napravnik
23Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kathleen McGinnis
6Veterans Affairs Connecticut Healthcare System, West Haven, CT, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gregory D Kirk
1Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA
4Division of Infectious Diseases, Department of Medicine, Johns Hopkins School of Medicine, Baltimore, MD, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Timothy R Sterling
24Vanderbilt Tuberculosis Center, Vanderbilt University School of Medicine, Nashville, Tennessee, USA
25Division of Infectious Diseases, Department of Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Richard D Moore
26Division of General Internal Medicine, Department of Medicine, Johns Hopkins School of Medicine, Baltimore, MD, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Parastu Kasaie
1Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

ABSTRACT

Importance Estimating the medical complexity of people aging with HIV can inform clinical programs and policy to meet future healthcare needs.

Objective To project the prevalence of comorbidities and multimorbidity among people with HIV (PWH) using antiretroviral therapy (ART) in the US through 2030.

Design Agent-based simulation model

Setting HIV clinics in the United States in the recent past (2020) and near future (2030)

Participants In 2020, 674,531 PWH were using ART; 9% were men and 4% women with history of injection drug use; 60% were men who have sex with men (MSM); 8% were heterosexual men and 19% heterosexual women; 44% were non-Hispanic Black/African American (Black); 32% were non-Hispanic White (White); and 23% were Hispanic.

Exposure(s) Demographic and HIV acquisition risk subgroups

Main Outcomes and Measures Projected prevalence of anxiety, depression, stage ≥3 chronic kidney disease (CKD), dyslipidemia, diabetes, hypertension, cancer, end-stage liver disease (ESLD), myocardial infarction (MI), and multimorbidity (≥2 mental or physical comorbidities, other than HIV).

Results We projected 914,738 PWH using ART in the US in 2030. Multimorbidity increased from 58% in 2020 to 63% in 2030. The prevalence of depression and/or anxiety was high and increased from 60% in 2020 to 64% in 2030. Hypertension and dyslipidemia decreased, diabetes and CKD increased, MI increased steeply, but there was little change in cancer and ESLD. Among Black women with history of injection drug use (oldest demographic subgroup in 2030), CKD, anxiety, hypertension, and depression were most prevalent and 93% were multimorbid. Among Black MSM (youngest demographic subgroup in 2030), depression was highly prevalent, followed by hypertension and 48% were multimorbid. Comparatively, 67% of White MSM were multimorbid in 2030 (median age in 2030=59 years) and anxiety, depression, dyslipidemia, CKD, and hypertension were highly prevalent.

Conclusion and relevance The distribution of multimorbidity will continue to differ by race/ethnicity, gender, and HIV acquisition risk subgroups, and be influenced by age and risk factor distributions that reflect the impact of social disparities of the health on women, people of color, and people who use drugs. HIV clinical care models and funding are urgently required to meet the healthcare needs of people with HIV in the next decade.

Question How will the prevalence of multimorbidity change among people with HIV (PWH) using antiretroviral therapy in the US from 2020 to 2030?

Findings In this agent-based simulation study using data from the NA-ACCORD and the CDC, multimorbidity (≥2 mental/physical comorbidities other than HIV) will increase from 58% in 2020 to 63% in 2030. The composition of comorbidities among multimorbid PWH vary by race/ethnicity, gender, and HIV acquisition risk group.

Meaning HIV clinical programs and policy makers must act now to identify resources and care models to meet the increasingly complex medical needs of PWH over time, particularly mental healthcare needs.

Competing Interest Statement

KN Althoff serves on the scientific review board for TrioHealth Inc and as a consultant to the All of Us Research Program. MJ Gill has been an Hoc member on national HIV Advisory Boards of Merck, Gilead and ViiV. C Wong is currently employed by Regeneron Pharmaceuticals Inc and contributed to this article as a prior trainee of Johns Hopkins University. All other co-authors report no competing interests.

Funding Statement

This research was supported by R01 AG053100 (PI: KN Althoff) from the National Institute on Aging, National Institutes of Health (NIH). PK was supported through the National Institution of Allergy and Infectious Diseases, NIH (Career development award, K01AI138853). EPH was supported through the National Institute on Aging, NIH (R01AG069575) and the Jerome and Celia Reich Endowed Scholar Award. The NA-ACCORD is supported by National Institutes of Health grants U01AI069918, F31AI124794, F31DA037788, G12MD007583, K01AI093197, K01AI131895, K23EY013707, K24AI065298, K24AI118591, K24DA000432, KL2TR000421, N01CP01004, N02CP055504, N02CP91027, P30AI027757, P30AI027763, P30AI027767, P30AI036219, P30AI050409, P30AI050410, P30AI094189, P30AI110527, P30MH62246, R01AA016893, R01DA011602, R01DA012568, R01AG053100, R24AI067039, R34DA045592, U01AA013566, U01AA020790, U01AI038855, U01AI038858, U01AI068634, U01AI068636, U01AI069432, U01AI069434, U01DA036297, U01DA036935, U10EY008057, U10EY008052, U10EY008067, U01HL146192, U01HL146193, U01HL146194, U01HL146201, U01HL146202, U01HL146203, U01HL146204, U01HL146205, U01HL146208, U01HL146240, U01HL146241, U01HL146242, U01HL146245, U01HL146333, U24AA020794, U54GM133807, UL1RR024131, UL1TR000004, UL1TR000083, UL1TR002378, Z01CP010214 and Z01CP010176; contracts CDC-200-2006-18797 and CDC-200-2015-63931 from the Centers for Disease Control and Prevention, USA; contract 90047713 from the Agency for Healthcare Research and Quality, USA; contract 90051652 from the Health Resources and Services Administration, USA; the Grady Health System; grants CBR-86906, CBR-94036, HCP-97105 and TGF-96118 from the Canadian Institutes of Health Research, Canada; Ontario Ministry of Health and Long Term Care, and the Government of Alberta, Canada. Additional support was provided by the National Institute Of Allergy And Infectious Diseases (NIAID), National Cancer Institute (NCI), National Heart, Lung, and Blood Institute (NHLBI), Eunice Kennedy Shriver National Institute Of Child Health & Human Development (NICHD), National Human Genome Research Institute (NHGRI), National Institute for Mental Health (NIMH) and National Institute on Drug Abuse (NIDA), National Institute On Aging (NIA), National Institute Of Dental & Craniofacial Research (NIDCR), National Institute Of Neurological Disorders And Stroke (NINDS), National Institute Of Nursing Research (NINR), National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Institute on Deafness and Other Communication Disorders (NIDCD), and National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). These data were collected by cancer registries participating in the National Program of Cancer Registries (NPCR) of the Centers for Disease Control and Prevention (CDC). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health, or the US Center for Disease Control and Prevention, or Regeneron Pharmaceuticals Inc.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The Johns Hopkins Bloomberg School of Public Health Institutional Review Board determined the PEARL study meets criteria permissible under the 2018 Common Rule as of August 31, 2021. This committee has allowed our study to proceed without ongoing continuing review through August 17, 2024.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Footnotes

  • Funding Statement: This research was supported by R01 AG053100 (PI: KN Althoff) from the National Institute on Aging, National Institutes of Health (NIH). PK was supported through the National Institution of Allergy and Infectious Diseases, NIH (Career development award, K01AI138853). EPH was supported through the National Institute on Aging, NIH (R01AG069575) and the Jerome and Celia Reich Endowed Scholar Award.

  • The NA-ACCORD is supported by National Institutes of Health grants U01AI069918, F31AI124794, F31DA037788, G12MD007583, K01AI093197, K01AI131895, K23EY013707, K24AI065298, K24AI118591, K24DA000432, KL2TR000421, N01CP01004, N02CP055504, N02CP91027, P30AI027757, P30AI027763, P30AI027767, P30AI036219, P30AI050409, P30AI050410, P30AI094189, P30AI110527, P30MH62246, R01AA016893, R01DA011602, R01DA012568, R01AG053100, R24AI067039, R34DA045592, U01AA013566, U01AA020790, U01AI038855, U01AI038858, U01AI068634, U01AI068636, U01AI069432, U01AI069434, U01DA036297, U01DA036935, U10EY008057, U10EY008052, U10EY008067, U01HL146192, U01HL146193, U01HL146194, U01HL146201, U01HL146202, U01HL146203, U01HL146204, U01HL146205, U01HL146208, U01HL146240, U01HL146241, U01HL146242, U01HL146245, U01HL146333, U24AA020794, U54GM133807, UL1RR024131, UL1TR000004, UL1TR000083, UL1TR002378, Z01CP010214 and Z01CP010176; contracts CDC-200-2006-18797 and CDC-200-2015-63931 from the Centers for Disease Control and Prevention, USA; contract 90047713 from the Agency for Healthcare Research and Quality, USA; contract 90051652 from the Health Resources and Services Administration, USA; the Grady Health System; grants CBR-86906, CBR-94036, HCP-97105 and TGF-96118 from the Canadian Institutes of Health Research, Canada; Ontario Ministry of Health and Long Term Care, and the Government of Alberta, Canada. Additional support was provided by the National Institute Of Allergy And Infectious Diseases (NIAID), National Cancer Institute (NCI), National Heart, Lung, and Blood Institute (NHLBI), Eunice Kennedy Shriver National Institute Of Child Health & Human Development (NICHD), National Human Genome Research Institute (NHGRI), National Institute for Mental Health (NIMH) and National Institute on Drug Abuse (NIDA), National Institute On Aging (NIA), National Institute Of Dental & Craniofacial Research (NIDCR), National Institute Of Neurological Disorders And Stroke (NINDS), National Institute Of Nursing Research (NINR), National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Institute on Deafness and Other Communication Disorders (NIDCD), and National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).

  • These data were collected by cancer registries participating in the National Program of Cancer Registries (NPCR) of the Centers for Disease Control and Prevention (CDC).

  • The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health, or the US Center for Disease Control and Prevention, or Regeneron Pharmaceuticals Inc.

  • NA-ACCORD Collaborating Cohorts and Representatives

    AIDS Clinical Trials Group Longitudinal Linked Randomized Trials: Constance A. Benson and Ronald J. Bosch

    AIDS Link to the IntraVenous Experience: Gregory D. Kirk

    Emory-Grady HIV Clinical Cohort: Vincent Marconi and Jonathan Colasanti

    Fenway Health HIV Cohort: Kenneth H. Mayer and Chris Grasso

    HAART Observational Medical Evaluation and Research: Robert S. Hogg, Viviane Lima, Zabrina Brumme, Julio SG

    Montaner, Paul Sereda, Jason Trigg, and Kate Salters

    HIV Outpatient Study: Kate Buchacz and Jun Li

    HIV Research Network: Kelly A. Gebo and Richard D. Moore

    Johns Hopkins HIV Clinical Cohort: Richard D. Moore

    John T. Carey Special Immunology Unit Patient Care and Research Database, Case Western Reserve University: Jeffrey Jacobson

    Kaiser Permanente Mid-Atlantic States: Michael A. Horberg

    Kaiser Permanente Northern California: Michael J. Silverberg

    Longitudinal Study of Ocular Complications of AIDS: Jennifer E. Thorne

    MACS/WIHS Combined Cohort Study: Todd Brown, Phyllis Tien, and Gypsyamber D’Souza

    Maple Leaf Medical Clinic: Graham Smith, Mona Loutfy, and Meenakshi Gupta

    The McGill University Health Centre, Chronic Viral Illness Service Cohort: Marina B. Klein Multicenter Hemophilia Cohort Study–II: Charles Rabkin

    Ontario HIV Treatment Network Cohort Study: Abigail Kroch, Ann Burchell, Adrian Betts, and Joanne Lindsay

    Parkland/UT Southwestern Cohort: Ank Nijhawan

    Retrovirus Research Center, Universidad Central del Caribe, Bayamon Puerto Rico: Angel M. Mayor

    Southern Alberta Clinic Cohort: M. John Gill and Raynell Lang

    Study of the Consequences of the Protease Inhibitor Era: Jeffrey N. Martin

    Study to Understand the Natural History of HIV/AIDS in the Era of Effective Therapy: Jun Li and John T. Brooks

    University of Alabama at Birmingham 1917 Clinic Cohort: Michael S. Saag, Michael J. Mugavero, and Greer Burkholder

    University of California at San Diego: Laura Bamford and Maile Karris

    University of North Carolina at Chapel Hill HIV Clinic Cohort: Joseph J. Eron and Sonia Napravnik

    University of Washington HIV Cohort: Mari M. Kitahata and Heidi M. Crane

    Vanderbilt Comprehensive Care Clinic HIV Cohort: Timothy R. Sterling, David Haas, Peter Rebeiro, and Megan Turner

    Veterans Aging Cohort Study: Kathleen McGinnis and Amy Justice

    NA-ACCORD Study Administration:

    Executive Committee: Richard D. Moore, Keri N. Althoff, Stephen J. Gange, Mari M. Kitahata, Jennifer S. Lee, Michael S. Saag, Michael A. Horberg, Marina B. Klein, Rosemary G. McKaig, and Aimee M. Freeman

    Administrative Core: Richard D. Moore, Keri N. Althoff, and Aimee M. Freeman

    Data Management Core: Mari M. Kitahata, Stephen E. Van Rompaey, Heidi M. Crane, Liz Morton, Justin McReynolds, and William B. Lober

    Epidemiology and Biostatistics Core: Stephen J. Gange, Jennifer S. Lee, Brenna Hogan, Elizabeth Humes, Sally Coburn, Lucas Gerace

  • Competing interests: KN Althoff serves on the scientific review board for TrioHealth Inc and as a consultant to the All of Us Research Program. MJ Gill has been an Hoc member on national HIV Advisory Boards of Merck, Gilead and ViiV. C Wong is currently employed by Regeneron Pharmaceuticals Inc and contributed to this article as a prior trainee of Johns Hopkins University.

  • The following co-authors report no competing interests:

  • 1. Cameron Stewart

  • 2. Elizabeth Humes

  • 3. Lucas Gerace

  • 4. Cynthia Boyd

  • 5. Kelly Gebo

  • 6. Amy C Justice

  • 7. Emily Hyle

  • 8. Sally Coburn

  • 9. Raynell Lang

  • 10. Michael J Silverberg

  • 11. Michael Horberg

  • 12. Viviane Lima

  • 13. Maile Karris

  • 14. Peter F Rebeiro

  • 15. Jennifer Thorne

  • 16. Ashleigh J Rich

  • 17. Heidi Crane

  • 18. Mari Kitahata

  • 19. Anna Rubtsova

  • 20. Sean Leng

  • 21. Vincent C Marconi

  • 22. Gypsyamber D’Souza

  • 23. Hyang Nina Kim

  • 24. Sonia Napravnik

  • 25. Kathleen McGinnis

  • 26. Gregory D Kirk

  • 27. Timothy R Sterling

  • 28. Richard D Moore

  • 29. Parastu Kasaie

Data Availability

All mathematical functions and input parameters used in the PEARL agent-based computer simulation model are available at www.PEARLHIVmodel.org.

https://pearlhivmodel.org/method_details.html

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Back to top
PreviousNext
Posted November 05, 2022.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
The projected prevalence of comorbidities and multimorbidity in people with HIV in the United States through the year 2030
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
The projected prevalence of comorbidities and multimorbidity in people with HIV in the United States through the year 2030
Keri N Althoff, Cameron Stewart, Elizabeth Humes, Lucas Gerace, Cynthia Boyd, Kelly Gebo, Amy C Justice, Emily Hyle, Sally Coburn, Raynell Lang, Michael J Silverberg, Michael Horberg, Viviane D Lima, M John Gill, Maile Karris, Peter F Rebeiro, Jennifer Thorne, Ashleigh J Rich, Heidi Crane, Mari Kitahata, Anna Rubtsova, Cherise Wong, Sean Leng, Vincent C Marconi, Gypsyamber D’Souza, Hyang Nina Kim, Sonia Napravnik, Kathleen McGinnis, Gregory D Kirk, Timothy R Sterling, Richard D Moore, Parastu Kasaie
medRxiv 2022.11.04.22281891; doi: https://doi.org/10.1101/2022.11.04.22281891
Digg logo Reddit logo Twitter logo Facebook logo Google logo LinkedIn logo Mendeley logo
Citation Tools
The projected prevalence of comorbidities and multimorbidity in people with HIV in the United States through the year 2030
Keri N Althoff, Cameron Stewart, Elizabeth Humes, Lucas Gerace, Cynthia Boyd, Kelly Gebo, Amy C Justice, Emily Hyle, Sally Coburn, Raynell Lang, Michael J Silverberg, Michael Horberg, Viviane D Lima, M John Gill, Maile Karris, Peter F Rebeiro, Jennifer Thorne, Ashleigh J Rich, Heidi Crane, Mari Kitahata, Anna Rubtsova, Cherise Wong, Sean Leng, Vincent C Marconi, Gypsyamber D’Souza, Hyang Nina Kim, Sonia Napravnik, Kathleen McGinnis, Gregory D Kirk, Timothy R Sterling, Richard D Moore, Parastu Kasaie
medRxiv 2022.11.04.22281891; doi: https://doi.org/10.1101/2022.11.04.22281891

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • HIV/AIDS
Subject Areas
All Articles
  • Addiction Medicine (214)
  • Allergy and Immunology (495)
  • Anesthesia (106)
  • Cardiovascular Medicine (1091)
  • Dentistry and Oral Medicine (194)
  • Dermatology (141)
  • Emergency Medicine (274)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (497)
  • Epidemiology (9747)
  • Forensic Medicine (5)
  • Gastroenterology (480)
  • Genetic and Genomic Medicine (2299)
  • Geriatric Medicine (221)
  • Health Economics (461)
  • Health Informatics (1548)
  • Health Policy (729)
  • Health Systems and Quality Improvement (600)
  • Hematology (236)
  • HIV/AIDS (500)
  • Infectious Diseases (except HIV/AIDS) (11623)
  • Intensive Care and Critical Care Medicine (615)
  • Medical Education (236)
  • Medical Ethics (67)
  • Nephrology (256)
  • Neurology (2137)
  • Nursing (133)
  • Nutrition (332)
  • Obstetrics and Gynecology (424)
  • Occupational and Environmental Health (516)
  • Oncology (1171)
  • Ophthalmology (363)
  • Orthopedics (128)
  • Otolaryngology (220)
  • Pain Medicine (145)
  • Palliative Medicine (50)
  • Pathology (308)
  • Pediatrics (693)
  • Pharmacology and Therapeutics (298)
  • Primary Care Research (265)
  • Psychiatry and Clinical Psychology (2168)
  • Public and Global Health (4640)
  • Radiology and Imaging (775)
  • Rehabilitation Medicine and Physical Therapy (451)
  • Respiratory Medicine (622)
  • Rheumatology (273)
  • Sexual and Reproductive Health (224)
  • Sports Medicine (208)
  • Surgery (250)
  • Toxicology (42)
  • Transplantation (120)
  • Urology (94)